WHATNEXT partner Patient Worthy recently reported on positive findings from a phase 2 clinical trial, which evaluated a combination treatment of Keytruda plus an experimental cancer vaccine designated mRNA-4157 (V940) for stage 3 and 4 melanoma that had been treated with surgical resection (removal).
Author Jessica Lynn writes:
After three years of follow-up data was collected, the researchers found that:
- The combination treatment reduced melanoma recurrence and/or mortality risk by approximately 49%. Additionally, the combination treatment reduced the risk of distant metastasis (the melanoma metastasizing, or spreading, to distant areas of the body) or death by 62% when compared to Keytruda as a monotherapy.
- Keytruda and mRNA-4157 (V940) were found to be relatively safe and well-tolerated. While some severe side effects did occur, the most common side effects were relatively mild. The highest reported side effects were injection site reactions, chills, and fatigue.
Check out the full story here.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. Patient Worthy and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
melanoma research skin cancer treatment
Last modified: April 2, 2024
